SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Scribe Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 2, 2026
$19.39−0.69 (-3.44%)
Close on Oct 19, 2026
- Market cap
- $48.01M
- P/E (TTM)
- –
- Dividend yield
- –
Scribe Therapeutics, Inc. cash flow statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 0.57
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 45.2%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –